Pharma


  • Thorny issues in pharma
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    How a 15-year-old Genzyme drug shortage became a legal smorgasbord of pharma’s thorniest issues

    Rare disease treatments, drug shortages, a market monopoly and march-in rights all play a role in the story of newly revived litigation against Sanofi’s Genzyme.

    By Alexandra Pecci • Feb. 26, 2024
  • Pharmaceutical Executives Testify At Senate Finance Committee Hearing On Drug Prices
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    AbbVie CEO Richard Gonzalez leaves a divisive Humira legacy and lasting impact on pharma

    Leading AbbVie to become one of the most successful pharmas in the world, Gonzalez also rubbed some critics the wrong way.

    By Feb. 22, 2024
  • digital pill Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Artificial intelligence & machine learning

    After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

    By PharmaVoice staff
  • chemist in lab with dropper
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    4 biotechs to watch in 2024

    A splashy IPO, first-in-class treatments and upcoming approval dates are a few reasons we’ve got our eyes on these biotechs this year.

    By Alexandra Pecci • Feb. 21, 2024
  • Joe Biden, Donald Trump
    Image attribution tooltip
    Chip Somodevilla/Getty Images via Getty Images
    Image attribution tooltip

    Biden or Trump: How deeply will 2024’s election outcome impact pharma?

    The election is still months away, but campaign promises are solidifying, and signal the benefits and drawbacks of each candidate for pharma.

    By Feb. 20, 2024
  • One of Kite Pharma's buildings.
    Image attribution tooltip
    Courtesy of Kite Pharma, Inc.
    Image attribution tooltip

    Kite’s next-gen CAR-T aims include quicker production and more disease targets

    While buzz builds around “off the shelf” CAR-T cell therapies, Kite is staying competitive with a shorter manufacturing turnaround and a focus on broadening applications.

    By Kelly Bilodeau • Feb. 20, 2024
  • IoT and AI design
    Image attribution tooltip
    Permission granted by Avenga
    Image attribution tooltip
    Sponsored by Avenga

    Value and potential of IoT and AI for chronic diseases treatment

    A significant growth is predicted for both AI and IoT in healthcare. By 2030, the AI market is expected to reach $187.95 billion USD, while the IoT market is projected to climb even higher to $312.7 billion USD.

    By Olena Domanska, Data Science Engineering Manager at Avenga • Feb. 20, 2024
  • pill loading
    Image attribution tooltip
    stock via Getty Images
    Image attribution tooltip

    ‘Hey, AI: Is Zoloft effective for me?’ Tech’s foray into predictive prescribing

    Researchers are unleashing the powers of AI for precision medicine, drug development and more.

    By Alexandra Pecci • Feb. 15, 2024
  • A man in a suit looking at the camera
    Image attribution tooltip
    Courtesy of Biogen
    Image attribution tooltip

    The roadblocks faced by Biogen are many, but execs point to an R&D-focused turnaround

    A disappointing few years for Biogen have led leadership to use new drug launches as fuel for an about-face.

    By Feb. 15, 2024
  • Niesha Foster, Pfizer
    Image attribution tooltip
    Permission granted by Pfizer
    Image attribution tooltip

    ‘I wish I could see the end of the day’ — a Pfizer exec on the fight for health equity

    The pharma giant’s leader of a collective devoted to health equity discusses how companies can put their money where their mouth is to reach communities in need.

    By Feb. 14, 2024
  • Drug pill question
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    These 4 drugs had tons of promise — and they flopped. What happened?

    No amount of excitement can prevent failures stemming from safety, efficacy, cost and other speed bumps along the way.

    By Alexandra Pecci • Feb. 13, 2024
  • vials
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    3 questions hanging over the Novo-Catalent deal

    As backlash builds for the recently announced matchup, critical questions remain over its impact.

    By Kelly Bilodeau • Feb. 13, 2024
  • Brain MRI
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    A new (old) mind-opening tool in the fight against Alzheimer’s disease

    A new use for an existing ultrasound technology is seeing early success in getting medications past the blood-brain barrier.

    By Kelly Bilodeau • Feb. 12, 2024
  • Yoshi Shitaka
    Image attribution tooltip
    Permission granted by Astellas
    Image attribution tooltip

    Astellas’ science chief on the leap into new technologies

    After a big 2023, Yoshi Shitaka said the company is banking on gene therapies, KRAS degraders and more to keep the momentum.

    By Feb. 9, 2024
  • Weight loss drug obesity Ozempic
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Big Pharma players Amgen, Roche and Pfizer seek to follow in Novo and Lilly’s weight loss footsteps

    While Novo Nordisk and Eli Lilly have a sizable lead in the quickly expanding GLP-1 market, Big Pharma peers are looking for a way in.

    By Feb. 8, 2024
  • anti-vaccine protestors with a stop vaccines sign on street
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip

    Pharma has a misinformation problem — and execs could be on the hook

    Investment heavyweights BlackRock and Glass Lewis want compensation clawbacks on execs who don’t protect a company’s reputation. 

    By Kelly Bilodeau • Feb. 7, 2024
  • Pill drug money balance
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    ‘Beginning of the end’ for small molecules? VCs brace for Medicare investment gap

    The "small molecule penalty" becomes even riskier for investors as the IRA negotiates prices, and VCs and lawmakers are looking to get a jump on those headwinds.

    By Feb. 6, 2024
  • Empty congressional chamber
    Image attribution tooltip
    Brendan Hoffman via Getty Images
    Image attribution tooltip

    Government hits patent thickets on multiple fronts

    Patent thickets are the latest target in lawmakers' bid to lower drug prices.

    By Alexandra Pecci • Feb. 5, 2024
  • syringe dollar sign shadow
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Could Novo, Lilly become first trillion-dollar healthcare companies?

    Explosive demand for weight loss drugs has propelled both companies to new heights. Here’s a look at the staggering growth, by the numbers.

    By Feb. 2, 2024
  • Merck sign
    Image attribution tooltip
    Marko Georgiev / Stringer via Getty Images
    Image attribution tooltip

    Merck keeps deal focus with Keytruda patent cliff on horizon

    The company is open to deals the size of its prior Acceleron and Prometheus buyouts. “We continue to believe we need more,” CEO Rob Davis said.

    By Ned Pagliarulo • Feb. 1, 2024
  • Pfizer CEO Albert Bourla
    Image attribution tooltip
    Drew Angerer via Getty Images
    Image attribution tooltip

    Pfizer’s COVID vax and antiviral sales have crashed. Will the ‘big bet’ on Seagen even the keel?

    In the first earnings call since the $43 billion Seagen deal closed, CEO Albert Bourla stressed that Pfizer is all in on the promise of ADCs to make up for COVID losses.

    By Feb. 1, 2024
  • AZ vaccine
    Image attribution tooltip
    Ricardo Ceppi via Getty Images
    Image attribution tooltip

    Co-inventor of AZ COVID-19 shot pivots from vaccine-linked name

    Barinthus Biotherapeutics wants to be known for more than its pandemic ties, CEO Bill Enright said.

    By Alexandra Pecci • Jan. 30, 2024
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip

    CAR-T developers respond to FDA black box warning

    Despite a recent safety warning from the FDA, companies such as BMS and J&J stress that the benefits of their cancer therapies still outweigh the risks.

    By Kelly Bilodeau • Jan. 30, 2024
  • A blood sample of HER2 for breast cancer diagnosis.
    Image attribution tooltip
    Md Saiful Islam Khan via Getty Images
    Image attribution tooltip

    AstraZeneca, Daiichi aim for first pan-tumor ADC approval

    A “tumor agnostic” FDA approval for the companies’ Enhertu would break new ground for antibody-drug conjugates. 

    By Ben Fidler • Jan. 29, 2024
  • Amylyx CEOs
    Image attribution tooltip
    Permission granted by Amylyx
    Image attribution tooltip
    Q&A

    ‘1 plus 1 equals 3’ — the co-CEO model in pharma

    Amylyx Pharmaceuticals’ co-founders and co-CEOs Josh Cohen and Justin Klee explain their approach to dual leadership and why it can be a good fit in life sciences.

    By Jan. 26, 2024
  • 2024 outlook
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The biggest questions hanging over pharma in 2024

    Key trends on the horizon in the life sciences this year.

    By Jan. 25, 2024